Cochrane · systematic review · CD007751
Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non‐diabetic chronic kidney disease
Cooper, TE, Teng, C, Tunnicliffe, DJ, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
5
No studies
6
Included studies
NR
No studies 6 · 50%Ungraded 1 · 8.3%Very low 2 · 16.7%Low 3 · 25%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyAngiotensin‐converting enzyme inhibitors versus placebo for early (stage 1 to 3) non‐diabetic chronic kidney disease
Population: adults with early (stage 1 to 3) non‐diabetic CKD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death (any cause) Angiotensin‐converting enzyme inhibitors vs placebo | RR 2 [0.26, 15.37] | 2 studies · 8873 participants | Low Downgraded: risk of bias |
CVD events: total (fatal and non‐fatal) Angiotensin‐converting enzyme inhibitors vs placebo | RR 0.97 [0.9, 1.05] | 2 studies · 8873 participants | Low Downgraded: risk of bias |
Adverse events: number reporting an adverse event Angiotensin‐converting enzyme inhibitors vs placebo | RR 1.33 [1.26, 1.41] | 2 studies · 8873 participants | Low Downgraded: risk of bias |
Kidney failure progression: doubling of SCr (mg/dL) Angiotensin‐converting enzyme inhibitors vs placebo | no estimate extracted | NR | No studies |
Angiotensin receptor blockers versus placebo for early (stage 1 to 3) non‐diabetic chronic kidney disease
Population: adults with early (stage 1 to 3) non‐diabetic CKD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death (any cause) Angiotensin receptor blockers vs placebo | no estimate extracted | 1 study · 226 participants | Ungraded |
CVD events Angiotensin receptor blockers vs placebo | no estimate extracted | NR | No studies |
Adverse events (number reporting an adverse event) Angiotensin receptor blockers vs placebo | RR 19.34 [1.14, 328.3] | 1 study · 226 participants | Very low Downgraded: risk of bias, imprecision |
Kidney failure progression: eGFR (mL/min/1.73m²) Angiotensin receptor blockers vs placebo | no estimate extracted | 1 study · 226 participants | Very low Downgraded: risk of bias, imprecision |
Angiotensin‐converting enzyme inhibitors versus angiotensin receptor blockers for early (stage 1 to 3) non‐diabetic chronic kidney disease
Population: adults with early (stage 1 to 3) non‐diabetic CKD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death (any cause) Angiotensin‐converting enzyme inhibitors vs angiotensin receptor blockers | no estimate extracted | NR | No studies |
CVD events Angiotensin‐converting enzyme inhibitors vs angiotensin receptor blockers | no estimate extracted | NR | No studies |
Adverse events Angiotensin‐converting enzyme inhibitors vs angiotensin receptor blockers | no estimate extracted | NR | No studies |
Kidney failure progression Angiotensin‐converting enzyme inhibitors vs angiotensin receptor blockers | no estimate extracted | NR | No studies |
ACEi compared to placebo for early (stage 1 to 3) non‐diabetic chronic kidney disease
Population: patients with early (stage 1 to 3) non‐diabetic chronic kidney disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality ‐ CKD stage 3 ACEi vs placebo | RR 1.8 [0.17, 19.27] | 2 studies · 1906 participants | Low Downgraded: imprecision, inconsistency, publication bias |
Cardiovascular events ‐ CKD stage 3 ACEi vs placebo | RR 0.87 [0.66, 1.14] | 2 studies · 1906 participants | Moderate Downgraded: imprecision, publication bias |